Anti-Rheumatic Drugs - Europe

Europe

In the European market for Anti-Rheumatic Drugs market, it is estimated that the revenue will reach US$5.33bn by the year 2024.
Moreover, it is anticipated that the revenue will exhibit an annual growth rate of 0.65% (CAGR 2024-2028), leading to a market volume of US$5.47bn by 2028.
When compared to other countries worldwide, United States is expected to generate the highest revenue in this market, with a projected value of US$37,550.00m in 2024.
In Europe, Germany is leading the way in the development and adoption of innovative anti-rheumatic drugs.

Key regions: France, Italy, Brazil, China, India

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Rheumatic Drugs in Europe has been increasing steadily over the past few years.

Customer preferences: Patients suffering from rheumatoid arthritis and other autoimmune diseases are the primary customers for Anti-Rheumatic Drugs. These patients are looking for drugs that can help reduce inflammation and pain associated with their conditions. They prefer drugs that have fewer side effects and can be easily administered.

Trends in the market: Germany is the largest market for Anti-Rheumatic Drugs in Europe. The country has a large aging population, which is more susceptible to autoimmune diseases. The demand for Anti-Rheumatic Drugs is also increasing in France, Italy, and Spain. The market is expected to grow in these countries due to the rising prevalence of autoimmune diseases and the increasing availability of biologic drugs.

Local special circumstances: In the UK, the National Health Service (NHS) is the primary healthcare provider. The NHS has been promoting the use of biosimilars, which are cheaper alternatives to biologic drugs. This has led to a decrease in the sales of biologic drugs in the UK. However, the demand for Anti-Rheumatic Drugs is still high due to the increasing prevalence of autoimmune diseases.

Underlying macroeconomic factors: The increasing prevalence of autoimmune diseases is the primary macroeconomic factor driving the growth of the Anti-Rheumatic Drugs market in Europe. The aging population in Europe is also contributing to the growth of the market. The availability of biologic drugs and biosimilars is another factor that is driving the growth of the market. The increasing awareness about autoimmune diseases and the availability of effective treatments are also contributing to the growth of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.